Clinical trial NCT01239589: European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes
Official title: European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Bipolar Manic Episode
Keywords: Patients admitted as for an acute bipolar manic episode
Description of management patterns and hospital stay in patients admitted for acute bipolar manic episode and treated with either quetiapine IR or quetiapine XR
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-11-11
Enrollment: 1280
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with Bipolar Disorder (ICD-10).admitted due to a acute manic episode and treated with quetiapine IR or quetiapine XR during the hospitalization period

Brief summary: This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with Bipolar Disorder (ICD-10).
* Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
* Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria:

* Patients in which BD is not the main reason for hospitalization
* Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
* Patients receiving both quetiapine IR and XR during the same hospitalization period.

Primary outcomes:
measure: Length of hospital stay
Secondary outcomes:
measure: Use of resources
measure: Treatments used
measure: Demographics
Other outcomes:
Locations:
city: Assebroek
country: Belgium
facility: Research Site
city: Bertrix
country: Belgium
facility: Research Site
city: Brugge
country: Belgium
facility: Research Site
city: Elsene
country: Belgium
facility: Research Site
city: Gent
country: Belgium
facility: Research Site
city: Godinne
country: Belgium
facility: Research Site
city: Koksijde
country: Belgium
facility: Research Site
city: Malle
country: Belgium
facility: Research Site
city: Marchienne-au-Pont
country: Belgium
facility: Research Site
city: Montignies-Sur-Sambre
country: Belgium
facility: Research Site
city: Ottignies
country: Belgium
facility: Research Site
city: Overpelt
country: Belgium
facility: Research Site
city: Roeselaere
country: Belgium
facility: Research Site
city: Split
country: Croatia
facility: Research Site
city: Zagreb
country: Croatia
facility: Research Site
city: Augustenborg
country: Denmark
facility: Research Site
city: Bispebjerg
country: Denmark
facility: Research Site
city: Br�nderslev
country: Denmark
facility: Research Site
city: Odense
country: Denmark
facility: Research Site
city: Helsingin Kaupunki
country: Finland
facility: Research Site
city: Jyv�skyl�
country: Finland
facility: Research Site
city: Kellokoski
country: Finland
facility: Research Site
city: Tammisaari
country: Finland
facility: Research Site
city: Ulm
country: Germany
facility: Research Site
state: Baden-W�rttemberg
city: Cham
country: Germany
facility: Research Site
state: Bayern
city: Neu�tting
country: Germany
facility: Research Site
state: Bayern
city: Regensburg
country: Germany
facility: Research Site
state: Bayern
city: Wasserburg am Inn
country: Germany
facility: Research Site
state: Bayern
city: W�rzburg
country: Germany
facility: Research Site
state: Bayern
city: Greifswald
country: Germany
facility: Research Site
state: Mecklenburg- Vorpommern
city: Bielefeld
country: Germany
facility: Research Site
state: Niedersachsen
city: Hildesheim
country: Germany
facility: Research Site
state: Niedersachsen
city: Liebenburg
country: Germany
facility: Research Site
state: Niedersachsen
city: Bochum
country: Germany
facility: Research Site
state: Nordrhein-Westfalen
city: Berlin
country: Germany
facility: Research Site
city: Ceglie Messapica
country: Italy
facility: Research Site
state: Brindisi
city: San Pietro Vernotico
country: Italy
facility: Research Site
state: Brindisi
city: Lamezia Terme
country: Italy
facility: Research Site
state: Catanzaro
city: Loc. S. Marciano (Sora)
country: Italy
facility: Research Site
state: Frosinone
city: S. Agata Militello
country: Italy
facility: Research Site
state: Messina
city: Conegliano
country: Italy
facility: Research Site
state: Treviso
city: Ascoli Piceno
country: Italy
facility: Research Site
city: Bologna
country: Italy
facility: Research Site
city: Cosenza
country: Italy
facility: Research Site
city: Cuneo
country: Italy
facility: Research Site
city: Ferrara
country: Italy
facility: Research Site
city: Foggia
country: Italy
facility: Research Site
city: Mestre
country: Italy
facility: Research Site
city: Pisa
country: Italy
facility: Research Site
city: Roma
country: Italy
facility: Research Site
city: Sassari
country: Italy
facility: Research Site
city: Teramo
country: Italy
facility: Research Site
city: Adana
country: Turkey
facility: Research Site
city: Ankara
country: Turkey
facility: Research Site
city: Ayd?n
country: Turkey
facility: Research Site
city: Bolu
country: Turkey
facility: Research Site
city: Diyarbakir
country: Turkey
facility: Research Site
city: Elazig
country: Turkey
facility: Research Site
city: Erzurum
country: Turkey
facility: Research Site
city: Istanbul
country: Turkey
facility: Research Site
city: Kayseri
country: Turkey
facility: Research Site
city: Konya
country: Turkey
facility: Research Site
city: Manisa
country: Turkey
facility: Research Site
city: Samsun
country: Turkey
facility: Research Site
city: Sanliurfa
country: Turkey
facility: Research Site
city: Sivas
country: Turkey
facility: Research Site
city: Trabzon
country: Turkey
facility: Research Site
city: Zonguldak
country: Turkey
facility: Research Site
city: Winsford
country: United Kingdom
facility: Research Site
state: Cheshire
city: Dartford
country: United Kingdom
facility: Research Site
state: Kent
city: Ealing
country: United Kingdom
facility: Research Site
state: London
city: Prescot
country: United Kingdom
facility: Research Site
state: Merseyside
city: Norwich
country: United Kingdom
facility: Research Site
state: Norfolk
city: Taunton
country: United Kingdom
facility: Research Site
state: Somerset
city: Cannock
country: United Kingdom
facility: Research Site
state: Staffordshire
city: Chertsey
country: United Kingdom
facility: Research Site
state: Surrey
city: Wolverhampton
country: United Kingdom
facility: Research Site
state: West Midlands
city: Pulborough
country: United Kingdom
facility: Research Site
state: West Sussex
city: Bradford
country: United Kingdom
facility: Research Site
state: Yorkshire
city: Bury St Edmunds
country: United Kingdom
facility: Research Site
city: Coventry
country: United Kingdom
facility: Research Site
city: Hull
country: United Kingdom
facility: Research Site
city: Leeds
country: United Kingdom
facility: Research Site
city: Leicester
country: United Kingdom
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
city: Newcastle (Upon Tyne)
country: United Kingdom
facility: Research Site
Study officials:
References:
citation: Karamustafalioglu O, Reif A, Atmaca M, Gonzalez D, Moreno-Manzanaro M, Gonzalez MA, Medina E, Bellomo A. Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME). BMC Psychiatry. 2014 Aug 31;14:246. doi: 10.1186/s12888-014-0246-3.